匹伐他汀对急性冠状动脉综合征疗效及安全性研究

The study on the tissue effectiveness and safety of pitavastatin in patients with acute coronary syndrome

目的观察急性冠状动脉综合征(acute coronary syndrome,ACS)患者接受匹伐他汀应治疗的安全性及疗效。方法 60例ACS患者,含20例非ST段抬高心肌梗死(NSTEMI)服用1周匹伐他汀(力清之,4 mg/次,1次/d),观察其调脂疗效。同时比较NSTEMI患者服用匹伐他汀与阿托代他汀后PCI手术即刻疗效。结果 60例患者服用1周匹伐他汀,胆固醇(total cholesterol,TC)及低密度脂蛋白(low density lipoprotein,LDL)明显降低,且无肝肾功能及肌肉的损害;NSTEMI患者服用匹伐他汀与阿托代他汀PCI术后近期效果无显著差异,且匹伐他汀临床副作用明显小于阿托代他汀。结论对于ACS患者,无论是否行PCI手术治疗,服用1周匹伐他汀(4 mg/次,1次/d)强化治疗是安全有效的。

Objective To observe the effectiveness and safety by pitavastatin in patients with acute coronary syndrome（ACS）. Methods In this study, we administered pitavastatin （4 mg/d） for one week in 60 patients with ACS （20 NSTEMI） and then investigated the effectiveness. Patients with NSTEMI PCI were randomly assigned to two groups with open-label treatment with pitavastatin or atorvastatin. Results 60 patients treated with pitavastatin for one week lowered LDL-C and TC clearly, no damage to muscle, liver and kidney functions, and the same PCI result was detected in the group from pitavastatin to atorvastatin, the adverse effect was significantly reduced with pitavastatin treatment compared with that with atorvastatin. Conclusion Accordingly, it was demonstrated that pitavastatin （4 mg daily） strengthened treatment is useful for the patients with acute coronary syndrome whenever the patients for PCI or not.